Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Wegovy and Monjaro
GLP-1 receptor agonists offer significant health benefits but raise ethical concerns about long-term safety, access equity, and societal impacts.
GLP-1 agonists in addiction therapy – review
GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders.
Safety of GLP-1 receptor agonists in body contouring surgery- a systematic review
A systematic review found a possible but fragile signal for increased wound dehiscence with GLP-1 RA use in body contouring. No other significant perioperative complications were observed.
SemaGBA- A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis
The SemaGBA model simulates semaglutide's effects on metabolic and neural pathways, providing insights into its mechanisms of action.
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Tirzepatide treatment for 12 weeks resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
GLP-1 RAs and Kidney Cancer Risk- Methodological Considerations in Active-Compara
A recent study using target trial emulation found no increased kidney cancer risk with GLP-1 RAs compared to SGLT2 inhibitors, challenging prior findings.
GLP-1 Receptor Agonists and NAION
GLP-1 receptor agonists likely increase NAION risk approximately twofold, but this rare event does not outweigh their cardiovascular and metabolic benefits for most patients.
GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain
GLP-1RAs show promise in reducing antipsychotic-induced weight gain without worsening psychiatric symptoms, offering a new approach for SPMI patients.
GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality
GLP-1 receptor agonists are associated with a statistically significant reduction in all-cause mortality for cancer patients with type 2 diabetes. This study highlights the potential benefits of GLP-1RAs in oncology settings.
GLP-1 therapies- an emerging approach for alcohol reduction?
A recent study found that semaglutide significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder and obesity, offering a promising new approach.